Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07416474 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 66 → 78 locationsv4
  2. Recruitment opened Start date changed from estimate of Mar 31, 2026 to Apr 3, 2026 · Site details revised at 66 of 66 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Mar 31, 2026 to Apr 3, 2026
    • Site details revised at 66 of 66 sites
  3. Primary endpoint revised Interventions: RC148 plus Carboplatin and paclitaxel (Drug), Tislelizumab plus Carboplatin and paclitaxel (Drug) to RC148 plus Carboplatin and Paclitaxel (Drug), Tislelizumab plus Carboplatin and Paclitaxel (Drug) · Secondary endpoints revised (6) · Site details revised at 2 of 66 sites · 2 morev2 Show 5 more changesShow less
    • Interventions: RC148 plus Carboplatin and paclitaxel (Drug), Tislelizumab plus Carboplatin and paclitaxel (Drug) to RC148 plus Carboplatin and Paclitaxel (Drug), Tislelizumab plus Carboplatin and Paclitaxel (Drug)
    • Secondary endpoints revised (6)
    • Site details revised at 2 of 66 sites
    • Eligibility criteria expanded, about 3 words
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.
Trial Details
NCT Number NCT07416474
Lead Sponsor RemeGen Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 574 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov